Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 20/20 | 0.53 |
| ▸ | SLC5A1 | P13866 | 12/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19415582 | 1.00 | SLC5A2 (0.53) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL13568132 | 1.00 | SLC5A2 (0.53) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL13483179 | 1.00 | SLC5A2 (0.53) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL13464107 | 0.92 | SLC5A2 (0.49) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL14012864 | 0.92 | SLC5A2 (0.55) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL13445692 | 0.92 | SLC5A2 (0.48) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL13707330 | 0.92 | SLC5A2 (0.55) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL14282116 | 0.92 | SLC5A2 (0.48) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL24105602 | 0.91 | SLC5A2 (0.59) | SLC5A2SLC5A1 | |
| SCHEMBL3798869 | 0.91 | SLC5A2 (0.59) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2312944-B1 | DEUTERATED BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS INC (US) | 2018-09-05 | — | — | EP | disclosed |
| US-9439901-B2 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives | PFIZER INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9439901-B2 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives | PFIZER INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9439901-B2 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives | PFIZER INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9439902-B2 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives | PFIZER INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9439902-B2 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives | PFIZER INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9439902-B2 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives | PFIZER INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9308204-B2 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives | PFIZER INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-9308204-B2 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives | PFIZER INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-9308204-B2 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives | PFIZER INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-20100063141-A1 | DEUTERATED BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| US-7662790-B2 | Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-16 | — | — | US | disclosed |
| WO-2010009243-A1 | DEUTERATED BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010009243-A1 | DEUTERATED BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
| EP-1874787-B1 | GLUCOPYRANOSYL-SUBSTITUTED (HETEROARYLOXY-BENZYL)-BENZENE DERIVATIVES AS SGLT INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2009-12-30 | — | — | EP | disclosed |
| EP-1874787-A1 | GLUCOPYRANOSYL-SUBSTITUTED (HETEROARYLOXY-BENZYL)-BENZENE DERIVATIVES AS SGLT INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2008-01-09 | — | — | EP | disclosed |
| WO-2007000445-A1 | GLUCOPYRANOSYL-SUBSTITUTED BENZYL-BENZENE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-04 | — | — | WO | disclosed |
| US-20070004648-A1 | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture | HIMMELSBACH FRANK | 2007-01-04 | — | — | US | disclosed |
| US-20060234953-A1 | Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-10-19 | — | — | US | disclosed |
| WO-2006108842-A1 | GLUCOPYRANOSYL-SUBSTITUTED (HETEROARYLOXY-BENZYL)-BENZENE DERIVATIVES AS SGLT INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004648-A1 | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture | UGGT1, GYS2, UGT2B7 | SLC5A2 7/4885SLC5A1 6/4885ADRA2A 321/4885 |
| US-20060234953-A1 | Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture | UGGT1, UGT2B7, GYS2 | SLC5A2 9/4885SLC5A1 6/4885ADRA2A 224/4885 |
| US-20100063141-A1 | DEUTERATED BENZYLBENZENE DERIVATIVES AND METHODS OF USE | SLC5A1, SLC5A2, SLC2A4 | SLC5A2 2/4885SLC5A1 1/4885ADRA2A 1354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.